STOCK TITAN

Aurora Cannabis to Host Second Quarter 2025 Investor Conference Call

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), a leading global medical cannabis company, has announced its upcoming second quarter 2025 earnings conference call scheduled for Wednesday, November 6, 2024, at 8:00 a.m. Eastern Time. The financial results will be released before market opening on the same day. Chairman and CEO Miguel Martin and CFO Simona King will host the conference call and Q&A session.

Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), una delle principali aziende globali nel settore della cannabis medica, ha annunciato la sua prossima conferenza telefonica sui risultati finanziari del secondo semestre 2025, programmata per mercoledì 6 novembre 2024, alle 8:00 ora orientale. I risultati finanziari saranno pubblicati prima dell'apertura del mercato lo stesso giorno. Il Presidente e CEO Miguel Martin e il CFO Simona King guideranno la conferenza telefonica e la sessione di domande e risposte.

Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), una de las principales empresas de cannabis médica a nivel mundial, ha anunciado su próxima conferencia telefónica sobre los resultados del segundo trimestre de 2025, programada para el miércoles 6 de noviembre de 2024, a las 8:00 a.m. hora del este. Los resultados financieros se publicarán antes de la apertura del mercado el mismo día. El presidente y CEO Miguel Martin y la CFO Simona King serán los encargados de la conferencia telefónica y de la sesión de preguntas y respuestas.

오로라 캐나비스 (NASDAQ: ACB) (TSX: ACB)는 세계적인 의료용 대마초 회사로, 2025년 2분기 실적 컨퍼런스 콜을 2024년 11월 6일 수요일 오전 8시 동부 표준시에 예정하고 있음을 발표했습니다. 재무 결과는 같은 날 시장 개장 전에 발표될 것입니다. 회장 겸 CEO 미겔 마르틴CFO 시모나 킹이 컨퍼런스 콜 및 질문과 응답 세션을 주최할 예정입니다.

Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), une entreprise mondiale leader dans le domaine du cannabis médical, a annoncé sa prochaine conférence téléphonique sur les résultats du deuxième trimestre 2025, prévue pour mercredi 6 novembre 2024, à 8h00, heure de l'Est. Les résultats financiers seront publiés avant l'ouverture du marché le même jour. Le président et CEO Miguel Martin et la CFO Simona King animeront la conférence téléphonique et la séance de questions-réponses.

Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), ein führendes globales Unternehmen im Bereich medizinisches Cannabis, hat seine bevorstehende Telefonkonferenz zu den Ergebnissen des zweiten Quartals 2025 angekündigt, die für Mittwoch, den 6. November 2024, um 8:00 Uhr Ostküstenzeit angesetzt ist. Die finanziellen Ergebnisse werden am selben Tag vor der Markteröffnung veröffentlicht. Vorsitzender und CEO Miguel Martin sowie CFO Simona King werden die Telefonkonferenz und die Frage-Antwort-Runde leiten.

Positive
  • None.
Negative
  • None.

NASDAQ | TSX: ACB

EDMONTON, AB, Oct. 24, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today announced today that it has scheduled a conference call to discuss the results for its second quarter 2025 on Wednesday, November 6, 2024 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the second quarter 2025 before the opening of markets that same day.

Conference Call Details

DATE:

Wednesday, November 6, 2024

TIME:

8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time

WEBCAST:

Click Here

Miguel Martin, Chairman and Chief Executive Officer, and Simona King, Chief Financial Officer, will host the conference call and question and answer period. This weblink has also been posted to the Company's "Investor Info" link at https://www.auroramj.com/investors/ under "Events".

About Aurora Cannabis

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and South America. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult- use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on X and LinkedIn.

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

For Media:                                         

For Investors:

Michelle Lefler                                   

ICR, Inc.

VP, Communications & PR               

Investor Relations

media@auroramj.com                       

aurora@icrinc.com

Forward Looking Statements

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the timing for the release of the Company's Fiscal 2025 Q2 financial statements and the conference call to discuss the results.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-to-host-second-quarter-2025-investor-conference-call-302286648.html

SOURCE Aurora Cannabis Inc.

FAQ

When will Aurora Cannabis (ACB) report its Q2 2025 earnings?

Aurora Cannabis will report its Q2 2025 earnings before market opening on Wednesday, November 6, 2024.

What time is Aurora Cannabis (ACB) Q2 2025 earnings call?

Aurora Cannabis's Q2 2025 earnings conference call is scheduled for Wednesday, November 6, 2024, at 8:00 a.m. Eastern Time (6:00 a.m. Mountain Time).

Who will host Aurora Cannabis (ACB) Q2 2025 earnings call?

The earnings call will be hosted by Chairman and CEO Miguel Martin and CFO Simona King.

Aurora Cannabis Inc. Common Shares

NASDAQ:ACB

ACB Rankings

ACB Latest News

ACB Stock Data

327.96M
54.66M
13.38%
4.8%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Edmonton